Abstract
PARPi therapies (olaparib, niraparib, rucaparib) have different adverse event (AE) profiles, which may lead to meaningful variation in the costs of AE management. The aim of this analysis was to estimate the total AE costs of monotherapy PARPi maintenance in women with newly diagnosed advanced ovarian cancer (NDOC) and women with platinum-sensitive relapsed ovarian cancer (PSROC) from a US healthcare perspective.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
